Biote projects 2026 revenue above $175M and adjusted EBITDA above $25M as recall-driven disruption delays procedure growth (NASDAQ:BTMD)
· seekingalpha.com
Biote (BTMD) Q2 2026 earnings call recap: recall impact, guidance cut, procedure volume recovery plans, supplements growth and M&A outlook—read key...
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...